Observational studyBMC anesthesiology2025
Retrospective evaluation of anesthesia management and clinical outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Observational study in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06398678 (Retrospective Evaluation of Anesthesia Management and Clinical Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Evaluation of Anesthesia Management and Clinical Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is used as an effective multimodal treatment option for patients with peritoneal malignancies. In this retrospective study, the anesthetic management of CRS + HIPEC procedures performed in our hospital between 2020 and 2024 and the postoperative course of the patients were investigated.
methodsThe present study included 22 patients who underwent CRS + HIPEC at our hospital. Preferred solutions for perioperative fluid management were balanced crystalloid, colloid and albumin. The mean duration of surgery was 326 and the mean duration of anesthesia was 344 min. 72.7% of the patients were female, and 27.3% were male, and the mean age was 58.6 years. ASA 3 score was found in 81.8% of the patients. While 68.2% of the patients did not receive preoperative chemotherapy, 31.8% received chemotherapy.
resultsIn the intraoperative period, the mean body temperature increased to 38.1 °C, and 6568 mL of crystalloid and 1325 mL of colloid were used for fluid management. The most prevalent metabolic alterations observed in the postoperative period were hypocalcemia (81.2%), hypokalemia (45.5%) and hyperglycemia (36%). A significant increase in lactate level (1.85 ± 1.93 mmol/L) and a decrease in bicarbonate level (4.12 ± 4.66 mmol/L) were observed after HIPEC. While 22.7% of the patients died in the postoperative period, 77.3% were discharged. Liberal fluid management strategies were employed; however, in recent cases, targeted fluid management has been introduced.
conclusionIt is imperative to emphasize that individualized fluid management and advanced monitoring during CRS + HIPEC procedure are critical in maintaining hemodynamic balance and reducing complications. CLINICAL
trial registrationThe Study was registered in clinicaltrials.gov (trial ID: NCT06398678 on 03/05/2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.